Abstract: Novel administration forms for acid-labile active compounds are described. The novel administration forms have no enteric layers and are suitable for oral administration.

Abstract: The invention relates to the combined use of the PDE4 inhibitor N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide, its pharmacologically tolerable salts or its N-oxide with a PDE3 inhibitor for the treatment of certain disease conditions such as, for example, acute or chronic obstructions of the bronchi.

Abstract: A composition comprising a combination of a compound of formula I 1

Abstract: The invention relates to the dihydrate of the magnesium salt of pantoprazole.

Abstract: The invention relates to novel inhibitors of human tryptase which are used in the pharmaceutical industry for the production of medicaments.

Abstract: Compounds of formula (1) in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases.

Abstract: Compounds of formula (1) in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases.

Abstract: Compounds of the formula I, in which R1, R2, R3 and R4 have the meanings indicated in the description, are novel active bronchial therapeutics.

Abstract: Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.

Abstract: Compounds of formula I, in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are efficacious bronchial therapeutics.

Abstract: The invention relates to the dihydrate of the magnesium salt of pantoprazole.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and R3 are hydrogen, 1-4C-alkyl, or halogen; R4, R5, R6, and R9 are hydrogen or 1-4C-alkyl; R7 and R8 are hydrogen, 1-4C-alkyl, 1-4C-alkoxy, or halogen; A is 1-7C-alkylene, 2-7C-alkenylene, 3-7C-cycloalkylene, or phenylene; G is hydrogen, hydroxyl, 1-7C-alkyl, 1-4C-alkyl substituted by fluorine, 2-7C-alkenyl, 3-7C-cycloalkyl, a mono- or di-1-4C-alkylcarbamoyl or -thiocarbamoyl, N-1-4C-alkyl-N′-cyanoamidino, 1-N-1-4C-alkylamino-2-nitroethylene, N-2-propynyl-N′-cyanoamidino, aminosulfonylamidino, —N(R10)R11, the part of the compound of formula (I) bonded to A, glucopyranoside, or a cyclic system or bicyclic system which is optionally substituted by R12 and R13; X is oxygen, N-1-4C-alkyl, NH, or S; Y is oxygen, N-1-4C-alkyl, NH, S, 1,4-piperazinylene, or 1,4-piperidinylene; Z is oxygen, N-1-4C-alkyl, NH, S, or CO; m is from 1 to 7; n is from 0 to 4; t is 0, 1, or 2; and u is 0 or 1, and their salts suitable for controllin

Abstract: Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.

Abstract: Compounds 8,9-diethoxy-2-methyl-6-[4(p-toluenesulfonamide) phenyl]-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridine and 9-ethoxy-8-methoxy-2-methyl-6-[4-(p-toluenesulfonamido)phenyl]-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridine and medicament compositions based thereon are useful for treating airway disorders, high blood pressure disorders and concomitant disorders connected therewith.

Abstract: Tetrahydropyrido compounds of formula (I) in which the substituents have the meanings mentioned in the description, are suitable for the prevention or treatment of gastrointestinal diseases.

Abstract: Compounds of formula I, wherein Het represents a heterocycle having the meaning and R1, R2, R3 and R4 have the meanings as given in the description are novel effective bronchial therapeutics.

Abstract: Compounds of formula I in which R1, R2, R3 and A have the meaning set forth in the specification, are selective cyclic nucleotide phosphodiesterase (PDE) inhibitors useful as therapeutics in human and veterinary medicine. They are distinguished by low toxicity, good enteral absorption (high bioavailability), a wide therapeutic breadth and absence of significant side effects.

Abstract: Novel administration form for acid-labile active compounds are described. The novel administration forms have no enteric layers and are suitable for oral administration.

Abstract: A diseased state based on acute or chronic obstruction of vessels and/or bronchi, acute or chronic inflammation and/or edema formation is advantageously treated by the combined administration of a PDE inhibitor with either an adenylate cyclase agonist or a guanylate cyclase agonist to a subject in need of such therapy. Administration can be either concurrent or in either order.

Abstract: Novel administration form for acid-labile active compounds are described. The novel administration forms have no enteric layers and are suitable for oral administration.